The Use of Lectins as Tools to Combat SARS-CoV-2

Area of Science:

• Virology
• Biochemistry
• Immunology

Background:

• The emergence of SARS-CoV-2 in 2019 necessitates novel therapeutic strategies.
• Lectins, carbohydrate-binding proteins, are being investigated as potential antiviral agents.
• The SARS-CoV-2 Spike protein interacts with host cell receptors ACE2, CD147, and DC-SIGNR.

Purpose of the Study:

• To review lectins with potential for COVID-19 treatment.
• To highlight lectins with demonstrated in vivo and in vitro antiviral activity.
• To discuss the mechanism of action and clinical applications of lectins.

Main Methods:

• Literature review of studies on lectins and viral infections.
• Analysis of lectin binding to viral glycoproteins and host cell receptors.
• Evaluation of existing data on lectin antiviral activity.

Main Results:

• Mannose-binding lectin, Griffithsin, and BanLec are identified as promising candidates.
• Lectins may inhibit viral fusion by binding to host cell receptors or the viral Spike protein.
• Antiviral activity of lectins has been observed in both in vitro and in vivo studies.

Conclusions:

• Development of new antiviral treatments, including lectins, remains crucial despite vaccine advancements.
• Lectins offer a potential therapeutic avenue for viral infections like COVID-19.
• Further research into lectin mechanisms and clinical efficacy is warranted.